Proteolysis targeting chimeras (PROTACs) in oncology: a review of patents and regulatory considerations.

ABSTRACT:

Introduction

Proteolysis Targeting Chimeras (PROTACs) represents a groundbreaking advancement in drug discovery and targeted protein degradation. Unlike traditional small-molecule inhibitors, PROTACs leverage the cell's natural protein degradation machinery to selectively degrade pathogenic proteins, offering significant therapeutic potential for previously undruggable targets and complex diseases such as cancer and neurodegenerative disorders. Understanding the regulatory landscape governing their approval is crucial as their development accelerates.

Areas covered

This review provides an overview of recent patents, regulatory considerations, emerging concerns, and future perspectives of PROTACs in cancer management.

Expert opinion

From a regulatory perspective, PROTA

SUBMITTER: M S 

PROVIDER: S-EPMC12367099 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature